CIK 0001598646
- Non-accelerated filer
- Smaller reporting company
Minerva Neurosciences, Inc.
Sign in to watch- Ticker
- NERV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 260784194
- Phone
- +1 617-600-7373
- Business address
- 1500 DISTRICT AVENUE, BURLINGTON, MA, 01803
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 29 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-12-13 | Davidson Michael Chief Medical Officer | Grant or award · Employee Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2017-12-13 | Saoud Jay SVP and Head of R&D | Grant or award · Employee Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2017-12-13 | Race Geoff EVP, CFO & CBO | Grant or award · Employee Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2017-12-11 | Russell Richard E. President | Grant or award | +40,000 | 40,000 | ||
| 2017-12-11 | Russell Richard E. President | Grant or award · Employee Stock option (Right to Buy) | +775,000 | 775,000 | ||
| 2017-12-10 | HASLER HANS PETER Director | Grant or award · Option Grant (Right to Buy) | +40,000 | 40,000 | ||
| 2017-12-10 | DOYLE WILLIAM F Director | Grant or award · Option Grant (Right to Buy) | +40,000 | 40,000 | ||
| 2017-09-01 | Saoud Jay SVP and Head of R&D | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2017-08-29 | JOHNSON & JOHNSON 10% owner | Other disposition | −3,892,256 | $0.00 | $389 | 0 |
| 2017-07-24 | Vandervelpen Nico Director | Returned to the company · Stock Option (Right to Buy) | −25,000 | 0 | ||
| 2017-07-24 | Vandervelpen Nico Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2017-07-24 | Vandervelpen Nico Director | Returned to the company · Stock Option (Right to Buy) | −12,500 | 0 | ||
| 2017-07-24 | Vandervelpen Nico Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-07-24 | Vandervelpen Nico Director | Returned to the company · Stock Option (Right to Buy) | −12,500 | 0 | ||
| 2017-07-24 | Vandervelpen Nico Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-06-01 | VAN HEEK G JAN Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2017-06-01 | Ahlholm Frederick W SVP, Chief Accounting Officer | Option exercise | +14,381 | $5.19 | $75K | 19,381 |
| 2017-06-01 | Ahlholm Frederick W SVP, Chief Accounting Officer | Option exercise | +7,250 | $4.71 | $34K | 26,631 |
| 2017-06-01 | Ahlholm Frederick W SVP, Chief Accounting Officer | Sale | −11,250 | $10.00 | $113K | 15,381 |
| 2017-06-01 | Ahlholm Frederick W SVP, Chief Accounting Officer | Sale | −10,381 | $11.00 | $114K | 5,000 |
Page 12 of 16 · 305 trades